PMID- 30153634 OWN - NLM STAT- MEDLINE DCOM- 20190201 LR - 20210109 IS - 1573-2517 (Electronic) IS - 0165-0327 (Print) IS - 0165-0327 (Linking) VI - 241 DP - 2018 Dec 1 TI - Serum and plasma brain-derived neurotrophic factor and response in a randomized controlled trial of riluzole for treatment resistant depression. PG - 514-518 LID - S0165-0327(18)30518-4 [pii] LID - 10.1016/j.jad.2018.08.075 [doi] AB - BACKGROUND: Serum brain-derived neurotrophic factor (BDNF) is decreased in individuals with major depressive disorder (MDD). Pre-clinical and clinical reports suggest that the glutamate release inhibitor riluzole increases BDNF and may have antidepressant properties. Here we report serum (sBDNF) and plasma (pBDNF) levels from a randomized controlled, adjunctive, sequential parallel comparison design trial of riluzole in MDD. METHODS: Serum and plasma BDNF samples were drawn at baseline and weeks 6 and 8 from 55 subjects randomized to adjunctive treatment with riluzole or placebo for 8 weeks. RESULTS: Riluzole responders had lower baseline serum (19.08 ng/ml [SD 9.22] v. 28.80 ng/ml [9.63], p = 0.08) and plasma (2.72 ng/ml [1.07] v. 4.60 ng/ml [1.69], p = 0.06) BDNF compared to non-responders at a trend level. This pattern was nominally seen in placebo responders for baseline pBDNF to some degree (1.21 ng/ml [SD 1.29] v. 3.58 ng/ml [SD 1.67], p = 0.12) but not in baseline sBDNF. LIMITATIONS: A number of limitations warrant comment, including the small sample size of viable BDNF samples and the small number of riluzole responders. CONCLUSIONS: Preliminary evidence reported here suggests that lower baseline BDNF may be associated with better clinical response to riluzole. CI - Copyright (c) 2018. Published by Elsevier B.V. FAU - Wilkinson, Samuel T AU - Wilkinson ST AD - Yale School of Medicine, 100 York St, STE 2J, New Haven, CT 06511, United States. Electronic address: samuel.wilkinson@yale.edu. FAU - Kiselycznyk, Carly AU - Kiselycznyk C AD - Yale School of Medicine, 100 York St, STE 2J, New Haven, CT 06511, United States. FAU - Banasr, Mounira AU - Banasr M AD - Campbell Family Mental Health Research Institute of CAMH (Centre of Addiction and Mental Health), Toronto, ON, Canada. FAU - Webler, Ryan D AU - Webler RD AD - Yale School of Medicine, 100 York St, STE 2J, New Haven, CT 06511, United States. FAU - Haile, Colin AU - Haile C AD - Baylor College of Medicine, Houston, TX, United States; Michael E. DeBakey VA Medical Center, Houston, TX, United States. FAU - Mathew, Sanjay J AU - Mathew SJ AD - Baylor College of Medicine, Houston, TX, United States; Michael E. DeBakey VA Medical Center, Houston, TX, United States. LA - eng GR - R01 MH085054/MH/NIMH NIH HHS/United States GR - R01 MH085050/MH/NIMH NIH HHS/United States GR - R01 MH085055/MH/NIMH NIH HHS/United States GR - K12 HS023000/HS/AHRQ HHS/United States GR - R25 MH071584/MH/NIMH NIH HHS/United States GR - T32 MH062994/MH/NIMH NIH HHS/United States GR - L30 MH111000/MH/NIMH NIH HHS/United States PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, N.I.H., Extramural PT - Research Support, U.S. Gov't, Non-P.H.S. PT - Research Support, U.S. Gov't, P.H.S. DEP - 20180818 PL - Netherlands TA - J Affect Disord JT - Journal of affective disorders JID - 7906073 RN - 0 (Antidepressive Agents) RN - 0 (Brain-Derived Neurotrophic Factor) RN - 0 (Excitatory Amino Acid Antagonists) RN - 7LJ087RS6F (Riluzole) SB - IM MH - Adolescent MH - Adult MH - Aged MH - Antidepressive Agents/therapeutic use MH - Brain-Derived Neurotrophic Factor/*blood MH - Depressive Disorder, Major/*drug therapy/physiopathology MH - Depressive Disorder, Treatment-Resistant/*drug therapy/physiopathology MH - Excitatory Amino Acid Antagonists/*therapeutic use MH - Female MH - Humans MH - Male MH - Middle Aged MH - Plasma MH - Riluzole/*therapeutic use MH - Serum MH - Young Adult PMC - PMC6140345 MID - NIHMS1505412 OTO - NOTNLM OT - BDNF OT - MDD OT - Riluzole COIS- Conflict of Interest: SJM has received funding from the National Institute of Mental Health, Department of Veterans Affairs, PCORI, and Janssen Research & Development. He has received consulting fees from Alkermes, Allergan, Cerecor, Fortress Biotech, Otsuka, and Valeant. He is also supported by the Johnson Family Chair for Research in Psychiatry at Baylor College of Medicine. STW has received consulting fees from Janssen Research & Development. CK, MB, RW and CH have no disclosures. EDAT- 2018/08/29 06:00 MHDA- 2019/02/02 06:00 PMCR- 2019/12/01 CRDT- 2018/08/29 06:00 PHST- 2018/03/12 00:00 [received] PHST- 2018/07/02 00:00 [revised] PHST- 2018/08/12 00:00 [accepted] PHST- 2018/08/29 06:00 [pubmed] PHST- 2019/02/02 06:00 [medline] PHST- 2018/08/29 06:00 [entrez] PHST- 2019/12/01 00:00 [pmc-release] AID - S0165-0327(18)30518-4 [pii] AID - 10.1016/j.jad.2018.08.075 [doi] PST - ppublish SO - J Affect Disord. 2018 Dec 1;241:514-518. doi: 10.1016/j.jad.2018.08.075. Epub 2018 Aug 18.